NDASUBCUTANEOUSSOLUTION
Approved
Apr 2008
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
4
Clinical Trials (4)
An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
Started Feb 2020
A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
Started Jan 2020
Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)
Started Oct 2006
524 enrolled
Post-Operative Ileus (POI)
Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide
Started Oct 2006
Loss of Exclusivity
LOE Date
Dec 31, 2030
58 months away
Patent Expiry
Dec 31, 2030